NASDAQ NMS - GLOBAL MARKET · QURE

+3.34% · +$1.48 · Vol 1.1M

After hours · updated 18:35:03 ET

Uniqure NV

Biotechnology

$45.79

Card

Relationship Map

Follow $QURE

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $QURE by email

Veridion Score

BETALOW CONF · 5 of 6 factors measured

Stale score · Mon Sep 21 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET · QURE

Methodology

Tue Sep 22 snapshot unavailable for QURE. Cause unavailable.

Analyst data unavailable at compute time

QURE

Uniqure NV

Stale score · Mon Sep 21 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET

32/100

Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

32/ 100

Veridion Score

Lower range · LOW confidence · 5 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: LOW · 5 of 6 factors measured · Stale score · Mon Sep 21 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is QURE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move QURE next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Sep 21
Score
Score moved -27
59/Middle range -> 32/Lower range
Veridion score historySource

About Uniqure NV

PHARMACEUTICAL PREPARATIONS

Listed since

2014

Employees

221

Country

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$44.50

Day high

$45.80

Day low

$44.47

Previous close

$44.31

52W high

$70.59

-35.13% from high

52W low

$9.03

60% of range

Market cap

$3.1B

EPS

$-4.1400

Beta

-1.08

Shares out

69.4M

Volume

1.1M

0.99× rel vol

Avg volume

1.1M

VWAP

$45.11

Price history computed in-house

+6.24%

-5.33%

-6.26%

+231.09%

YTD

+91.35%

SMA 50 $44.54 · above

SMA 200 $29.29 · above

52W position 60%

QURE overview

Veridion Score

Registered · 2026-09-21

5 of 6 factors measured

Latest receipt rows

No recent disclosure on file.

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around QURE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

QURE insider activity

Uniqure NV

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not covered: this ticker is outside our Form 4 ingest scope — we have not looked

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

Form 4 evidence state

Not covered: this ticker is outside our Form 4 ingest scope — we have not looked.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in QURE

Congress tracker Open ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for QURE in the cached public ledger.

Federal contracts

QURE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for QURE in this window.

Lobbying spend

QURE lobbying filings, year to date.

Registered lobbying filings matched to Uniqure NV.

Not disclosed

Refresh interval: 12hSource: LDA disclosure filings

No lobbying filings on file for QURE in this window.

Analyst ratings

Sovereign unlock shows live analyst consensus for QURE.

Options

Sovereign unlock shows live options positioning for QURE.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Methodology

No related ticker met the data requirements for this rail.

Follow $QURE

Why is QURE moving today?

What can move QURE next.

QURE overview

Related filings and maps

QURE insider activity

QURE contract awards, year to date.

QURE lobbying filings, year to date.

Cross-references from this score page.

What can move QURE next.

QURE insider activity

Cross-references from this score page.